Summary
Becton, Dickinson and Company (BDX) reported a modest increase in revenues for the fiscal first quarter ending December 31, 2025, with total revenues reaching $5.252 billion, up 1.6% from the prior year. This growth was primarily driven by favorable foreign currency impacts and moderate volume increases, despite some pricing headwinds. Net income rose to $382 million, resulting in diluted earnings per share of $1.34, a significant increase from $1.04 in the prior year, reflecting improved operational performance and the favorable impact of foreign currency. The company also announced the completion of a major transaction: the spin-off of its Biosciences and Diagnostic Solutions business, combined with Waters Corporation, which resulted in a significant cash distribution of $4 billion to BD. This strategic move is expected to reshape the company's future focus and financial structure. Operationally, the company saw varied performance across its segments. While Connected Care and Interventional segments showed strong revenue growth, driven by specific product lines like Advanced Patient Monitoring and Peripheral Intervention respectively, the Medical Essentials segment experienced slight declines. The Life Sciences segment, which is being divested, saw a notable decrease in revenues. Looking ahead, BD is prioritizing innovation, commercial excellence, and operational efficiency under its 'Excellence Unleashed' strategy. The significant cash influx from the Waters transaction provides ample opportunity for strategic deployment, including accelerated share repurchases and debt reduction, aiming to enhance shareholder value.
Financial Highlights
53 data points| Revenue | $5.25B |
| Cost of Revenue | $2.84B |
| Gross Profit | $2.41B |
| R&D Expenses | $306.00M |
| SG&A Expenses | $1.39B |
| Operating Expenses | $4.70B |
| Operating Income | $552.00M |
| Net Income | $382.00M |
| EPS (Basic) | $1.34 |
| EPS (Diluted) | $1.34 |
| Shares Outstanding (Basic) | 285.58M |
| Shares Outstanding (Diluted) | 285.85M |
Key Highlights
- 1Total revenues increased by 1.6% to $5.252 billion for the quarter ended December 31, 2025, driven by foreign currency effects and volume.
- 2Net income grew to $382 million, with diluted EPS reported at $1.34, up from $1.04 in the prior year.
- 3The company completed a significant transaction on February 9, 2026, spinning off its Biosciences and Diagnostic Solutions business and combining it with Waters Corporation, receiving a $4 billion cash distribution.
- 4The Connected Care segment demonstrated robust revenue growth of 5.5%, while the Interventional segment saw a 5.8% increase.
- 5Life Sciences segment revenues declined by 8.3%, reflecting ongoing divestiture activities.
- 6BD returned $299 million to shareholders through dividends and repurchased $250 million of its common stock during the quarter.
- 7The company expects to utilize approximately $2 billion of the cash received from the Waters transaction for share repurchases in Q2 FY2026.